Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation

Bone Marrow Transplant. 2015 Dec;50(12):1574-7. doi: 10.1038/bmt.2015.182. Epub 2015 Aug 17.

Authors

G Battipaglia^{1

2}, A Ruggeri¹, E Brissot¹, A-C Mamez¹, F Malard¹, R Belhocine¹, A Vekhoff¹, F Giannotti¹, T Ledraa¹, M Labopin^{1

3}, M-T Rubio^{1

4}, M Mohty^{1

3

4}

Affiliations

¹ Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
² Department of Hematology and Marrow Transplantation, University Federico II of Naples, Naples, Italy.
³ Université Pierre & Marie Curie, Paris, France.
⁴ INSERM, UMRs 938, Paris, France.

PMID: 26281029
DOI: 10.1038/bmt.2015.182

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Allografts
Female
Hematopoietic Stem Cell Transplantation*
Humans
Male
Middle Aged
Receptors, Fc / administration & dosage*
Recombinant Fusion Proteins / administration & dosage*
Recombinant Fusion Proteins / adverse effects
Thrombocytopenia / drug therapy*
Thrombocytopenia / etiology
Thrombopoietin / administration & dosage*
Thrombopoietin / adverse effects

Substances

Receptors, Fc
Recombinant Fusion Proteins
Thrombopoietin
romiplostim